Doctors who are in different specialties may struggle to be able to connect with each other. This is something that they have been working on for years and it has put somewhat of a hinderance on what doctors are able to do because they are really only able to study different treatment methods in their chosen area of medicine. This is something that has changed over the years and is now something that is going to be different based on the information that Oncotarget has for people. Because of the way that Oncotarget was put together, doctors can make the choice to connect with each other and can learn more about the different things that are going on in other areas of medicine.
It not only allows doctors the chance to branch out in their own field of medicine but to also branch out and find out more information about the other types of medicine available to people.Since Oncotarget was created by an oncologist, it is something that has a primary focus in oncology and different methods for cancer treatment but it has been able to help people who are in other areas of medicine, too. Because of the opportunities that people have when they are studying medicine, Oncotarget has been a great change and has been something that people will be able to benefit from no matter what they are doing.
Oncotarget has been easy for people to try and make all of the right choices and that has given people the chance to learn more about medicine.When the peer review publication was first started, it was something that people could learn about and get more information from. It is now something that even students are able to learn about in the different areas of medicine. No matter what type of doctor a student is studying to be, he or she can get the best experience possible from Oncotarget. They can learn about the different things that can be done to help people who have cancer as well as the different things that can be done for people who have other issues.
Today’s medical research on cancer is sorely lacking; researchers need more data. The data exists in abundance, but clinicians need to combine both genomic and therapeutic data to find working cancer treatments that are applicable to patients. Once this is accomplished, researchers can start working on definitive treatments to combat cancer.
Medications for cancer have varying success rates, and a given drug that may work for one patient doesn’t necessarily work for another. The problem is that researchers are not given all the variables that make up every patient’s physical response, such as other medication, family history and other illnesses. Without this information, clinicians are left with a trial and error approach to treatment.
Eric Lefkovsky, the co-founder and CEO of Tempus, is determined to improve treatment care for cancer patients. Tempus is a platform that collects patient data and allows researchers to use the information. They look for patterns to show how a given treatment affects groups of people. The technology is dedicated to analyzing genomic data in clinical settings in order to improve cancer research treatment effectiveness. Levkofsky started Tempus after his wife was diagnosed with cancer and he saw the need for oncologists to have free access to data.
Levkofsky graduated from the University of Michigan Law School and moved on to become a successful entrepreneur. In addition to Tempus, Lefkovsky is a founding partner of Lightbank, the co-founder and chairman of Groupon and co-founder of Uptake Technologies. He also works for several other technology media based companies.
In 2006, he founded the Lefkovsky Family Foundation with his wife to advance charitable, scientific, medical or educational organizations. Lefkovsky has donated to numerous projects and foundations over the years, but arguably the most notable contributions have been his generous donations to health care and research. He has given over $1,000,000 to different healthcare organizations, including John Hopkins, the Cystic Fibrosis Foundation and the University of Texas MD Anderson Cancer Center.
To know more visit @: lefkofskyfoundation.com/